Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Core One Labs's share price for the quarter that ended in Dec. 2023 was €0.23. Core One Labs's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 46.73 Mil. Therefore, Core One Labs's market cap for the quarter that ended in Dec. 2023 was €10.75 Mil.
Core One Labs's quarterly market cap
declined
from Dec. 2022 (€19.65 Mil) to Sep. 2023 (€11.03 Mil) and
declined
from Sep. 2023 (€11.03 Mil) to Dec. 2023 (€10.75 Mil).
Core One Labs's annual market cap
increased
from Dec. 2019 (€7.33 Mil) to Dec. 2020 (€51.14 Mil) but then
declined
from Dec. 2020 (€51.14 Mil) to Dec. 2021 (€10.35 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Core One Labs's Enterprise Value for Today is €7.43 Mil.
Core One Labs Market Cap Historical Data
The historical data trend for Core One Labs's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Core One Labs's Market Cap
For the Biotechnology subindustry, Core One Labs's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Core One Labs's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Core One Labs's Market Cap distribution charts can be found below:
* The bar in red indicates where Core One Labs's Market Cap falls into.
Core One Labs Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Core One Labs's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Core One Labs (FRA:LD6) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Core One Labs Market Cap Related Terms
Thank you for viewing the detailed overview of Core One Labs's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Core One Labs Inc is a psychedelic research and development life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. The Company operates a virtual clinic that assesses patients for the appropriateness of treatment plans for the use of medical cannabis to treat their symptoms. The Company partners with physicians and Health Canada's licensed producers for the provision of treatments, fulfillment of prescriptions, and sale of related products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LD6 has been successfully added to your 